The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma

Journal of the American Academy of Dermatology

Volumn 75, Issue 1, 2016, Pages 113-125.e5

  Dummer, Reinhard ^a   Guminski, Alexander ^b   Gutzmer, Ralf ^c   Dirix, Luc ^d   Lewis, Karl D ^e   Combemale, Patrick ^f   Herd, Robert M ^g   Kaatz, Martin ^h,i   Loquai, Carmen ^j   Stratigos, Alexander J ^k   Schulze, Hans Joachim ^l   Plummer, Ruth ^m   Gogov, Sven ⁿ   Pallaud, Celine ⁿ   Yi, Tingting ⁿ   Mone, Manisha ⁿ   Chang, Anne Lynn S ^o   Cornélis, Frank ^p   Kudchadkar, Ragini ^q   Trefzer, Uwe ^r   Lear, John T ^s   Sellami, Dalila ⁿ   Migden, Michael R ^t   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f CENTRE LÉON BÉRARD   (France)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h JENA UNIVERSITY HOSPITAL   (Germany)

ⁱ SRH Wald Klinikum Gera   (Germany)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY OF ATHENS   (Greece)

^l Fachklinik Hornheide   (Germany)

^m FREEMAN HOSPITAL   (United Kingdom)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^q EMORY UNIVERSITY   (United States)

^r Dermatologikum Berlin   (Germany)

^s UNIVERSITY OF MANCHESTER   (United Kingdom)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Advanced basal cell carcinoma; Basal Cell Carcinoma Outcomes with LDE225 Treatment study; Hedgehog pathway inhibitor; Locally advanced basal cell carcinoma; Metastatic basal cell carcinoma; Sonidegib

Indexed keywords

CREATINE KINASE; SONIDEGIB; VISMODEGIB; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; PYRIDINE DERIVATIVE; SMOOTHENED PROTEIN;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; BASAL CELL CARCINOMA; CANCER PATIENT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CARCINOMA, BASAL CELL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; SKIN NEOPLASMS; SMOOTHENED RECEPTOR; SURVIVAL RATE; YOUNG ADULT;

EID: 84962679495     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.02.1226     Document Type: Article

References (42)

1. A. Sekulic, A.R. Mangold, D.W. Northfelt, and P.M. LoRusso Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway Curr Opin Oncol 25 3 2013 218 223
2. N.R. Telfer, G.B. Colver, and C.A. Mortan Guidelines for the management of basal cell carcinoma Br J Dermatol 159 1 2008 35 48
3. M.R. Gailani, M. Stahle-Backdahl, D.J. Leffell, and et al. The role of the human homologue of drosophila patched in sporadic basal cell carcinomas Nat Genet 14 1 1996 78 81
4. J. Reifenberger, M. Wolter, C.B. Knobbe, and et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas Br J Dermatol 152 1 2005 43 51
5. S. Gupta, N. Takebe, and P. LoRusso Targeting the hedgehog pathway in cancer Ther Adv Med Oncol 2 4 2010 237 250
6. Cancer Council Australia/Australian Cancer Network 2008. Clinical practice guide. Basal cell carcinoma, squamous cell carcinoma (and related lesions) - a guide to clinical management in Australia. 2008. Available from: URL: http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Basal-cell-carcinoma-Squamous-cell-carcinoma-Guide-Nov-2008-Final-with-Corrigendums.pdf. Accessed January 23, 2015.
7. M. Trakatelli, C. Morton, E. Nagore, and et al. Update of the European guidelines for basal cell carcinoma management Eur J Dermatol 24 3 2014 312 329
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: basal cell and squamous cell skin cancer. V2.2014. Available from: URL: http://www.NCCN.org. Accessed January 23, 2015.
9. J. Dreier, P.F. Cheng, I. Bogdan Alleman, and et al. Basal cell carcinomas in a tertiary referral center: a systematic analysis Br J Dermatol 171 5 2014 1066 1072
10. J. Dreier, R. Dummer, L. Felderer, M. Nageli, S. Gobbi, and R. Kunstfeld Emerging drugs and combination strategies for basal cell carcinoma Expert Opin Emerg Drugs 19 3 2014 353 365
11. Australian Government. Department of Health and Ageing. Therapeutic Goods Administration. Australian public assessment report for Odomzo. 2015. Available from: URL: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=226544&agid=%28PrintDetailsPublic%29&actionid=1. Accessed November 9, 2015.
12. Swissmedic Swiss Agency for Therapeutic Products. Authorization of Odomzo. 2015. Available from: URL: https://www.swissmedic.ch/zulassungen/00153/00189/00200/02858/index.html?lang=en. Accessed July 7, 2015.
13. Odomzo (sonidegib) [package insert] 2015 Novartis Pharmaceuticals Corporation East Hanover, NJ
14. European Medicines Agency. CHMP summary of opinion for Odomzo. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion--Initial-authorisation/human/002839/WC500188762.pdf. Accessed July 7, 2015.
15. Erivedge (vismodegib) 2012 Genentech USA Inc [package insert]. South San Francisco, CA
16. Australian Government. Department of Health and Ageing. Therapeutic Goods Administration. Australian public assessment report for vismodegib. 2013. Available from: URL: http://www.tga.gov.au/auspar/auspar-vismodegib. Accessed January 23, 2015.
17. European Medicines Agency. CHMP summary of opinion for Erivedge. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion--Initial-authorisation/human/002602/WC500142522.pdf. Accessed January 23, 2015.
18. S. Pan, X. Wu, J. Jiang, and et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist ACS Med Chem Lett 1 13 2010 130 134
19. J. Rodon, H.A. Tawbi, A.L. Thomas, and et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors Clin Cancer Res 20 7 2014 1900 1909
20. M.R. Migden, A. Guminski, R. Gutzmer, and et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicenter, randomized, double-blind phase 2 trial Lancet Oncol 16 6 2015 716 728
21. World Health Organization WHO handbook for reporting results for cancer treatment 1979 World Health Organization Geneva (Switzerland)
22. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
23. US Department of Health and Human Services National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 2010 US Department of Health and Human Services Washington (DC)
24. Dummer R, Grichnik JM, Schwartz LH, et al. Composite assessment of treatment response in patients with locally advanced basal cell carcinoma (laBCC): efficacy with sonidegib using 2 sets of response criteria. Presented at: 5th European Post-Chicago Melanoma/Skin Cancer Meeting; June 25-26, 2015; Munich, Germany (abstract P.05).
25. R. Dummer, V.K. Sondak, J.M. Grichnik, and et al. Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): sonidegib efficacy using two sets of response criteria J Clin Oncol 33 suppl 2015 [abstract e20055]
26. A. Sekulic, M.R. Migden, A.E. Oro, and et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 366 23 2012 2171 2179
27. A. Sekulic, M.R. Migden, K. Lewis, and et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC J Am Acad Dermatol 72 6 2015 1021 1026.e8
28. A.L. Chang, J.A. Solomon, J.D. Hainsworth, and et al. Expanded access study of patients with advanced basal cell carcinoma treated with the hedgehog pathway inhibitor, vismodegib J Am Acad Dermatol 70 1 2013 60 69
29. European Medicines Agency. CHMP assessment report. Erivedge. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Public-assessment-report/human/002602/WC500146820.pdf. Accessed January 23, 2015.
30. A.J. Gajjar, S. Gururangan, I.A. Qaddoumi, and et al. A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): a Pediatric Brain Tumor Consortium study (PBTC 25B) J Clin Oncol 31 15 suppl 2013 [abstract 2035]
31. J. Goldman, S.G. Eckhardt, M.J. Borad, and et al. Phase 1 dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors Clin Cancer Res 21 5 2015 1002 1009
32. A. Jimeno, G.J. Weiss, W.H. Miller Jr., and et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors Clin Cancer Res 19 10 2013 2766 2774
33. P.M. Lorusso, C.M. Rudin, J.C. Reddy, and et al. Phase I trial of hedgehog pathway inhibitor (GDC-0449) in patients with refractory, locally-advanced or metastatic solid tumors Clin Cancer Res 17 8 2011 2502 2511
34. S. Sahebjam, L.L. Siu, and A.A. Razak The utility of hedgehog signaling pathway inhibition for cancer Oncologist 17 8 2012 1090 1099
35. L.L. Siu, K. Papadopoulos, S.R. Alberts, and et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors J Clin Oncol 28 15 suppl 2010 [abstract 2501]
36. J.Y. Tang, J.M. Mackay-Wiggan, M. Aszterbaum, and et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome N Engl J Med 366 23 2012 2180 2188
37. A.J. Wagner, W.A. Messersmith, M.N. Shaik, and et al. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors Clin Cancer Res 21 5 2015 1044 1051
38. A. Italiano, A. Le Cesne, C. Bellera, and et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute single-arm phase II collaborative study Ann Oncol 24 11 2013 2922 2926
39. M.S. Ally, S. Aasi, A. Wysong, and et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma J Am Acad Dermatol 71 5 2014 904 911.e1
40. N. Basset-Seguin, A. Hauschild, J.J. Grob, and et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial Lancet Oncol 16 6 2015 729 736
41. Plummer R, Lear J, Gutzmer R, et al. Efficacy following discontinuation of sonidegib treatment in patients with locally advanced basal cell carcinoma (laBCC). Presented at: 11th European Association of Dermato Oncology Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer. October 28-31, 2015. Marseille, France.
42. A. Otsuka, J. Dreier, P.F. Cheng, and et al. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma Clin Cancer Res 21 6 2015 1289 1297